News Image

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Provided By GlobeNewswire

Last update: Jan 13, 2025

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025

Read more at globenewswire.com

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (5/2/2025, 8:00:01 PM)

After market: 3.31 0 (0%)

3.31

+0.03 (+0.91%)



Find more stocks in the Stock Screener

Follow ChartMill for more